The present invention discloses a novel process for the preparation of ethyl 3-[5-(3-chloro-2-fluorobenzyl)-2.4-dimethoxy phenyl]-3-oxopropanoate of formula II, which is a key intermediate in the preparation of Eivitegravir, a drug used in the treatment of infection with the human immunodeficiency virus (HIV).